Healthtech Startup Fibroheal Woundcare Raises Pre-Series A Funding
Fibroheal plans to use the funds to strengthen its go-to-market strategy, expand its workforce, and invest in its medical devices product pipeline.
Healthtech startup Fibroheal Woundcare has raised INR 6.3 Cr in its pre-Series A funding round from existing promoters and new investors, including surgeons, medical professionals, and bankers.
The company also received an additional commitment of NR 10 Cr from current and new investors.
Fibroheal plans to use the funds to strengthen its go-to-market strategy, expand its workforce, and invest in its medical devices product pipeline.
Founded in 2017 by Vivek Mishra and Bharat Tandon, Fibroheal specializes in silk protein-based medical devices for wound care. Its products, including foams, mesh, and powders, are used to treat acute, chronic, traumatic, post-operative, and non-healing wounds, such as bedsores and infected C-section wounds.
The company’s products are currently available in over 500 hospitals across 19 states in India and are also sold on various e-commerce platforms.
Fibroheal Woundcare has previously raised funds from existing promoters, including Telama Investments, CCAMP, and KITVEN.
Fibroheal Woundcare is a biotech and healthcare start-up based in Bengaluru, India. They specialize in using silk proteins as biomaterials for wound healing.
Their focus is on active and advanced wound care management, offering a range of products designed to address various wound care needs, including tissue debridement, infection control, moisture balance, and scar management.
